When SCPs were combined with anti-PD1, there was a further decrease (30.6-% reduction) in tumor growth (Figure 1B), suggesting that SCPs could synergize with anti-PD1 to reduce the tumor burden in mice with MC-38 tumors. This evidence concerns the gene PDCD1 and neoplasm.